Seegene, Inc., the leading multiplex diagnostic assay developer, today 
announced that the company has exported over 10 million tests of Allple(TM) 
2019-nCoV Assay to over 60 countries, which accounts for a significant portion 
of globally performed COVID-19 test numbers.

Seegene's proactive decision to develop COVID-19 test kit with the capability 
of rapid assay development using its proprietary AI-based big data system 
allowed many countries to quickly expand the testing capacity, as the virus 
started swamping all across the globe.

The demand for Seegene's assay continues to rise as it gained reputation for 
its high quality and efficiency. The test has a unique feature that identifies 
3 different target genes (E, RdRP and N genes) in a single reaction tube using 
its own multiplex chemistry technologies, which allows for highly accurate 
results and maximizes the throughput for high volume testing. Combined with its 
automated system and advanced software, Seegene assay is globally proven to be 
effective in high volume testing which is the key component in controlling 
outbreak situations.  

Seegene currently exports over 3 million tests a week. The company will reach 
its manufacturing capacity over 20 million tests in May, and continue to scale 
up its production to fulfill the unmet and increasing demand from all over the 
world. 

"We have been taking on new challenges every day to keep up with the global 
need, as we continue to face unexpected issues in the process of explosive 
increase in production and exports. I am extremely proud of what we have been 
able to contribute to this fight against the virus and of the fact that our 
cutting edge molecular diagnostic technologies have played a part in this 
important fight" said Dr. Jong-Yoon Chun, CEO of Seegene.

Seegene also teamed up with its affiliate, Seegene Medical Foundation (SMF), 
one of the reference laboratories in Korea with the largest capacity for 
COVID-19 testing of up to 15,000 a day, to help countries in need for the virus 
test exponentially and in emergency. SMF is ready to report the test result 
within 24 hours upon the arrival of the samples from overseas. As the COVID-19 
pandemic continues to wreak havoc all around the globe, Seegene and SMF have 
been organized to do their part in providing the much needed tests and testing 
capacity. 

About Seegene
Seegene (KQ : 096530) is a global pioneer in symptom-based in vitro molecular 
diagnostics focusing on advancing science to develop multiplex molecular 
technologies and to manufacture multiplex in vitro diagnostic devices and 
reagents. Seegene's core enabling power is the passion for wide spreading of 
multiplex molecular diagnostics to improve the quality of life and health of 
people. Using its innovative proprietary technologies, Seegene has been making 
considerable contributions to giving the most economic and clinic-friendly 
molecular diagnostic solutions for infectious diseases, genetics, 
pharmacogenetics, and oncology. For more information, please visit 
www.seegene.com.

SOURCE: Seegene